Skip to main content

Table 1 Clinicopathological characteristics of patients with primary PCa

From: Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer

Characteristic

All

n = 66

Adeno-NEPC

n = 20

Adeno-PCa

n = 46

P

Age (years)

67.86 ± 7.05

68.65 ± 7.23

67.52 ± 7.02

0.837

Prostatectomy

   

0.308

 No

27 (40.9%)

11 (55.0%)

16 (34.8%)

 

 Yes

39 (59.1%)

9 (45.0%)

30 (65.2%)

 

Primary ADT

   

0.308

 No

39 (59.1%)

9 (45.0%)

30 (65.2%)

 

 Yes

27 (40.9%)

11 (55.0%)

16 (34.8%)

 

T staging

   

0.982

 T1

1 (1.5%)

0 (0.00%)

1 (2.2%)

 

 T2

13 (19.7%)

3 (15.0%)

10 (21.7%)

 

 T3

41 (62.1%)

14 (70.0%)

27 (58.7%)

 

 T4

11 (16.7%)

3 (15.0%)

8 (17.4%)

 

N staging

   

0.490

 N0

37 (56.1%)

9 (45.0%)

28 (60.9%)

 

 N1

29 (43.9%)

11 (55.0%)

18 (39.1%)

 

M staging

   

0.751

 M0

44 (66.7%)

12 (60.0%)

32 (69.6%)

 

 M1

22 (33.3%)

8 (40.0%)

14 (30.4%)

 

Gleason score

   

0.168

 < 7

1 (1.5%)

0 (0.00%)

1 (2.2%)

 

 7

24 (36.4%)

3 (15.0%)

21 (45.6%)

 

 > 7

41 (62.1%)

17 (85.0%)

24 (52.2%)

 

PSA (ng/L)

   

0.177

 < 10

9 (13.6%)

1 (5.0%)

8 (17.4%)

 

 10–20

12 (18.2%)

1 (5.0%)

11 (23.9%)

 

 > 20

45 (68.2%)

18 (90.0%)

27 (58.7%)

 

LDH (U/L)

   

0.207

 < 250

57 (86.4%)

15 (75.0%)

42 (91.3%)

 

 ≥ 250

9 (13.6%)

5 (25.0%)

4 (8.7%)

 

ALP (U/L)

   

0.894

 < 125

58 (87.9%)

17 (85.0%)

41 (89.1%)

 

 ≥ 125

8 (12.1%)

3 (15.0%)

5 (10.9%)

 
  1. Abbreviations: PCa Prostate cancer, NEPC Neuroendocrine prostate cancer, ADT Androgen deprivation therapy, PSA Prostate-specific antigen, LDH Lactate dehydrogenase, ALP Alkaline phosphatase